Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

207.63 -0.15 (-0.07%)
Official Closing Price Updated: 4:10 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,184,266
Open 207.53
Bid (Size) 207.44 (100)
Ask (Size) 208.00 (600)
Prev. Close 207.78
Today's Range 206.71 - 208.04
52wk Range 140.68 - 215.19
Shares Outstanding 2,628,679,824
Dividend Yield 2.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Blue-Chip Bull Run: Dow Jones Eyes 50,000 Milestone Amidst 2026 Technical Pivot
As the final bells of 2025 ring across the floor of the New York Stock Exchange, the Dow Jones Industrial Average (DJI) stands at a historic crossroads. After a year defined by a resilient "soft... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The 2025 Growth Postgame: Analyzing the AI Supercycle and Preparing for the 2026 'Agentic' Pivot
As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade

Performance

YTD
+44.2%
+44.2%
1 Month
+0.5%
+0.5%
3 Month
+16.8%
+16.8%
6 Month
+36.6%
+36.6%
1 Year
+42.6%
+42.6%

More News

Read More
News headline image
Johnson & Johnson Terminates Experimental Eczema Drug Study After It Fails To Show Benefit ↗
Via Stocktwits
News headline image
Johnson & Johnson Halts Atopic Dermatitis Study After Interim Analysis Miss ↗
Via Benzinga
News headline image
Baxter International (BAX) in 2025: A Deep Dive into the Transformation of a MedTech Giant
Via PredictStreet
Topics Economy Emissions Product Recall
News headline image
Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
This Dividend ETF Could Quietly Make You a Multimillionaire Over Time ↗
Via The Motley Fool
Topics ETFs
News headline image
Top 5 US Healthcare Stocks By Market Value ↗
Via Stocktwits
News headline image
Legal Seismic Shift: Johnson & Johnson Faces Record $1.5 Billion Talc Verdict as Bankruptcy Strategy Collapses
Via MarketMinute
Topics Bankruptcy Bonds Lawsuit
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
Via MarketMinute
Topics Economy
News headline image
The Dividend King Buy-and-Hold Strategy That Can Surge 100% in 10 Years ↗
Via The Motley Fool
News headline image
Johnson & Johnson Hit With Record $1.5 Billion US Verdict Over Talc Cancer Claim ↗
Via Benzinga
News headline image
The Great Consolidation: Why 2026 is Set to Become the 'Year of the Mega-Deal'
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report
Via Barchart.com
Topics ETFs
News headline image
Why a Minnesota Jury Ordered Johnson & Johnson To Pay $65.5 Million in Damages ↗
Via Benzinga
News headline image
The 10% Shadow: Analyzing the Growing Risk of a 30% Market Correction in 2026
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Want $10,000 in Passive Income? This Vanguard ETF Could Be Your Ticket to Making It Happen. ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
FDA Approves J&J's New 5-Minute Injection For Lung Cancer ↗
Via Benzinga
News headline image
The 2022 Playbook Returns: Why Investors are Building a 'Fortress 2026'
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
The Yield Search: Why Retirees are Swapping Growth for Defense in a Shifting 2025 Market
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
Rate Cuts Make These 3 Income ETFs More Attractive Than Ever ↗
Via MarketBeat
Topics ETFs
News headline image
The Emotional Rollercoaster: How Fear and Greed Shape Investor Behavior in Market Downturns
Via MarketMinute
Topics Bonds Economy Supply Chain

Frequently Asked Questions

Is Johnson & Johnson publicly traded?
Yes, Johnson & Johnson is publicly traded.
What exchange does Johnson & Johnson trade on?
Johnson & Johnson trades on the New York Stock Exchange
What is the ticker symbol for Johnson & Johnson?
The ticker symbol for Johnson & Johnson is JNJ on the New York Stock Exchange
What is the current price of Johnson & Johnson?
The current price of Johnson & Johnson is 207.63
When was Johnson & Johnson last traded?
The last trade of Johnson & Johnson was at 12/26/25 04:10 PM ET
What is the market capitalization of Johnson & Johnson?
The market capitalization of Johnson & Johnson is 545.79B
How many shares of Johnson & Johnson are outstanding?
Johnson & Johnson has 546B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.